IQV株価 $237.79 · 時価総額 $41.9bn
IQVIA HOLDINGS INC.
Services-Commercial Physical & Biological Research| 期 | 23/12 | 24/12 | 25/12 |
|---|---|---|---|
| 売上 | $15.0bn | $15.4bn | $16.3bn |
| 成長率 | — | 2.8% | 5.9% |
| 総利益 | $10.4bn | $10.8bn | $11.7bn |
| 総利益率 | 69.2% | 70.0% | 71.7% |
| 販管費 | $2.1bn | $2.0bn | $2.0bn |
| 販管費率 | 13.7% | 12.9% | 12.3% |
| 営利 | $2.0bn | $2.2bn | $2.2bn |
| 営利率 | 13.2% | 14.3% | 13.4% |
| 純利益 | $1.4bn | $1.4bn | $1.4bn |
| PSR | 2.79x | 2.72x | 2.57x |
| PGPR | 4.0x | 3.9x | 3.6x |
| PER | 30.8x | 30.5x | 30.8x |
| PBR | 6.93x | 6.90x | 6.44x |
| ネットキャッシュ | $-5.7bn | $-5.4bn | $-5.1bn |
| EV/EBITDA | 15.3x | 14.3x | 14.1x |
| Rule of 40 | — | 17.1% | 19.3% |
| セールス効率 | — | — | 12928.6% |
※Rule of 40は売上成長率+営業利益率、セールス効率は売上総利益増加÷販管費増加(販管費増のときのみ)
